Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CCR1 | P32246 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 2/20 | 0.35 |
| ▸ | CCR8 | P51685 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4429040 | 0.75 | LMNA (0.48) | MMP2TSHRCCR1CCR5CCR8 | |
| SCHEMBL1571887 | 0.74 | KDM4E (0.39) | MMP2TSHRCCR1CCR5CCR8 | |
| SCHEMBL51544 | 0.69 | ATM (0.41) | HSP90AA1EGFRNPC1RAB9A | |
| SCHEMBL9422646 | 0.69 | — | — | |
| SCHEMBL5894144 | 0.69 | MMP2 (0.35) | MMP2TSHRCCR1CCR5CCR8 | |
| SCHEMBL2361668 | 0.69 | EGFR (0.44) | KDM4EEGFR | |
| Hydrochloric Acid SCHEMBL10501335 | 0.68 | ATM (0.40) | HSP90AA1EGFRNPC1RAB9A | |
| SCHEMBL7657126 | 0.65 | CYP2A6 (0.32) | KDM4ELMNACYP3A4CYP2D6CYP2A6 | |
| SCHEMBL15349155 | 0.64 | KDM4E (0.35) | MMP2TSHRCCR1CCR5CCR8 | |
| SCHEMBL3577849 | 0.64 | PSMD14 (0.33) | PSMD14COPS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709853-A1 | METHODS OF PREVENTING ON-TARGET GENOTOXICITY INDUCED BY NUCLEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024235844-A1 | METHODS OF PREVENTING ON-TARGET GENOTOXICITY INDUCED BY NUCLEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-11-21 | — | — | WO | disclosed |
| WO-2023174352-A1 | CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 北京药明博锐生物科技有限公司 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023038858-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING COVID-19 | Edifice Health, Inc. (US) | 2023-03-16 | — | — | WO | disclosed |
| WO-2023027951-A1 | TREATMENT OF DISEASE USING IAGE AND MIG | Edifice Health, Inc. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20230042936-A1 | PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES AS CDK INHIBITORS | FUNDACION DEL SECTOR PUBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (F.S.P. CNIO) (ES) | 2023-02-09 | — | — | US | disclosed |
| EP-4009858-A1 | TREATMENT OF PREVENTION OF CARDIOVASCULAR DISEASE | Edifice Health, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11359011-B2 | Treatment and prevention of cardiovascular disease | Edifice Health, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| WO-2022093763-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING FRAILTY | Edifice Health, Inc. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20210380672-A1 | Treatment and Prevention of Cardiovascular Disease | Edifice Health, Inc. (US) | 2021-12-09 | — | — | US | disclosed |
| US-6964967-B2 | Substituted pyrido[2,3-d]pyrimidines and methods for their use | AMGEN, INC. (US) | 2005-11-15 | — | — | US | disclosed |
| US-20050075333-A1 | CXCR3 antagonists | TULARIK INC. | 2005-04-07 | — | — | US | disclosed |
| US-6794379-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; SKIN DISORDERS | TULARIK INC. | 2004-09-21 | — | — | US | disclosed |
| EP-1343505-A1 | CXCR3 ANTAGONISTS | Tularik Inc. (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030069234-A1 | CXCR3 antagonists | AMGEN INC. | 2003-04-10 | — | — | US | disclosed |
| US-20030055054-A1 | CXCR3 antagonists | TULARIK, INC. | 2003-03-20 | — | — | US | disclosed |
| US-20020169159-A1 | An acetamide derivative is useful for treatment of inflammatory and immune conditions and diseases; modulates the expressin and/or function of a chemokine receptor | TULARIK INC. (US) | 2002-11-14 | — | — | US | disclosed |
| WO-2002083143-A1 | CXCR3 ANTAGONISTS | TULARIK INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-4859672-A | Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone | RORER PHARMACEUTICAL CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
| US-4009166-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, CNS DEPRESSANTS | HISAMITSU PHARMACEUTICAL CO., INC. (JA) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075333-A1 | CXCR3 antagonists | CXCR3, CXCR1, CCR5 | MMP2 1370/4885TSHR 975/4885CCR1 9/4885 |
| US-20030069234-A1 | CXCR3 antagonists | CXCR3, CXCR1, CCR5 | MMP2 1370/4885TSHR 975/4885CCR1 9/4885 |
| US-20020169159-A1 | An acetamide derivative is useful for treatment of inflammatory and immune conditions and diseases; modulates the expressin and/or function of a chemokine receptor | CCR2, CCR1, ACKR3 | MMP2 2005/4885TSHR 1129/4885CCR1 2/4885 |
| US-20210380672-A1 | Treatment and Prevention of Cardiovascular Disease | SERPINA6, FABP3, CXCL8 | MMP2 637/4885TSHR 2503/4885CCR1 151/4885 |
| US-11359011-B2 | Treatment and prevention of cardiovascular disease | SERPINA6, FABP3, CXCL8 | MMP2 637/4885TSHR 2503/4885CCR1 151/4885 |
| US-20030055054-A1 | CXCR3 antagonists | CXCR3, CXCR1, CCR5 | MMP2 1370/4885TSHR 975/4885CCR1 9/4885 |
| US-20230042936-A1 | PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES AS CDK INHIBITORS | CDK7, CDK8, CDK9 | MMP2 3461/4885TSHR 3372/4885CCR1 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.